Peptide News Digest

#Pain

1 story

Research · View digest

MOTS-EM2, a Fusion of MOTS-c and an Opioid Peptide, Kept 78% of Its Pain Relief After Eight Daily Doses in Mice

Researchers at Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine joined the mitochondrial peptide MOTS-c to endomorphin-2, a natural opioid peptide. In mouse models of acute, inflammatory, and nerve pain, the fusion relieved pain longer than endomorphin-2 alone and retained 78.09% of its effect after eight daily injections, versus 20% for endomorphin-2. It slowed gut transit less and did not impair movement, but still showed some addiction potential, the team wrote in the International Journal of Peptide Research and Therapeutics.